Objective. To evaluate the associations between GCA and vascular diseases and other comorbidities in patients with GCA compared with non-vasculitis patients.
Introduction
GCA is the most common primary form of systemic vasculitis in older adults in Western countries. It involves large and medium-sized arteries, and especially branches of the proximal aorta [1] . It is very rare in patients <50 years, and the ACR considers patient age 550 years to be among the defining criteria for GCA [2] . Glucocorticoids are the primary treatment to control systemic inflammation and to prevent vision loss in GCA patients [3] . In many affected patients, systemic vasculitis-accelerated atherosclerosis has become a leading cause of death [4] , but data on the association of GCA with vascular disease remain inconclusive, with some studies suggesting increased risks for vascular disease [510] , while others suggest no association [1114] . Moreover, few studies have examined the epidemiology of vascular disease before GCA diagnosis, where important insights for better understanding the patient population and effective management of GCA are needed. There are also few studies with adequate quantitative data to assess the relationship between GCA and other comorbidities, such as hypertension and type 2 diabetes, that are risk factors for vascular disease.
We conducted this study to evaluate the associations between GCA and vascular diseases and other comorbidities in a cohort of GCA patients compared with a matched non-vasculitis cohort, and to examine whether associations differ according to sex and age.
Methods

Data source
Data were derived from the UK-based Clinical Practice Research Datalink (CPRD, formerly General Practice Research Database), a large primary care database that has been previously described in detail [15, 16] . Briefly, the CPRD is an ongoing longitudinal database that has collected data from over 500 general practices in the UK covering more than 8 million patients (around 6% of the UK population) since 1987. Because the general practitioner is the primary care giver for all patients in the UK National Health Service, no segment of the population is excluded from the CPRD and it has a representative age and sex distribution of the UK population. The information recorded includes patient demographics and characteristics, clinical diagnoses, drug prescriptions, consultant referrals, lab results and hospitalizations. Validation studies have shown the high quality of recorded prescriptions and diagnoses [1517] . This study was approved by the Independent Scientific Advisory Committee for Medicines and Healthcare products Regulatory Agency database research (protocol no: 15_051).
Study design and base population
This was a cohort study of all patients with a first-time diagnosis of GCA and 51 year of recorded medical history before the first GCA diagnosis code between 1 January 1990 and 31 December 2014. One year of history was required to ensure that we identified patients with newly diagnosed GCA and to capture pre-existing vascular diseases and other comorbidities. For each GCA patient, at least 1 and up to 10 random patients without diagnoses of any form of vasculitis were matched on age (±2 years), sex, general practice attended and years of history before the cohort entry date (date of first recorded GCA diagnosis or corresponding date for the matched non-vasculitis patient). Because the CPRD is a primary care database, the matched comparison patients as well as GCA patients were identified from a general patient population rather than a hospital or registry population. This means that health of the comparison patients is representative of the UK population of the same age and sex distribution as the GCA patients.
GCA definition GCA patients were those who had a diagnosis in their medical record of GCA, temporal arteritis or Horton disease based on Read codes and who were age 550 years at first diagnosis. Because glucocorticoids are the mainstay treatment for GCA and immunosuppressive therapy may be started as adjuvant therapy [18] , to be considered a valid case we required each patient to have two or more prescriptions for either glucocorticoids or immunosuppressive therapy, where the first prescription was within 6 months of the diagnosis date, and the two prescriptions were within 6 months of each other. Because some patients died or transferred out of their practice shortly after the diagnosis, they may not have had a chance to receive two or more of these prescriptions. To examine the impact of incomplete follow-up, we also included patients whose data collection ended within 6 months of the cohort entry date regardless of whether they had received two or more treatment prescriptions (3.2% of GCA patients). See Supplementary Fig. S1 , available at Rheumatology Online, for GCA patient selection. Note that 98% of the study GCA patients were treated with glucocorticoids. A similar definition of GCA has previously been validated in the CPRD and 90% of patients were found to be true cases [19] .
Vascular disease and other comorbidities
We assessed nine types of vascular diseases, that is, myocardial infarction (MI), angina pectoris, unspecified ischaemic heart disease, atherosclerosis, stroke/transient ischaemic attacks, peripheral vascular disease (PVD), heart failure, aortic aneurysm and venous thromboembolism (VTE, including deep vein thrombosis and pulmonary embolism). We also assessed 11 other comorbidities, all risk factors for vascular disease. These included atrial fibrillation, hypertension, dyslipidaemia, type 2 diabetes, obesity (based on BMI and diagnosis code where available), moderate to severe renal disease, depression, PMR, RA, psoriasis and cancer (except non-melanoma skin cancer). Although depression is not a well-known risk factor for vascular disease, it has been reported to be associated with risk of MI [20, 21] . All codes are available upon request.
Covariates
We collected information on smoking (current, former, never or unknown), BMI, alcoholism (yes or no) and exposure to aspirin, anti-hypertensive medicine, glucoselowering medicine, lipid-lowering medicine, NSAIDs and antidepressants, defined by the presence of two or more prescriptions within 1 year before cohort entry.
Statistical analysis
We collected the first recorded date for each type of vascular disease and other study comorbidity and compared it with the cohort entry date to distinguish pre-existing and incident conditions. For pre-existing vascular disease and other comorbidities, we compared frequencies between GCA patients and the non-vasculitis comparison patients using the chi-square test or Fisher's exact test. For incident vascular disease we estimated and compared the cumulative incidence of each type of vascular disease at 1, 3, 5 and 10 years of follow-up between GCA patients and the non-vasculitis comparison patients using Gray's test, adjusted for the competing risk of death [22, 23] . Patients with pre-existing vascular disease were excluded from the analyses of incident vascular disease. Each eligible patient was followed until the date of the first of the following: the first diagnosis of any type of vascular disease, the patient transferred out of the practice, the end of data collection or death. We also estimated and compared the cumulative incidence of each other comorbidity at 1, 3, 5 and 10 years of follow-up using Gray's test, adjusted for the competing risk of death. Patients with pre-existing comorbidities were excluded from their corresponding analyses. We used Cox regression to estimate, for each type of vascular disease and comorbidity the crude and adjusted hazard ratio (HR) comparing the GCA cohort with the cohort of non-vasculitis patients. Finally we repeated all analyses in subgroup populations stratified by sex and age (50 to <65, 65 to <80 and 580 years).
To examine the robustness of the results we conducted three sensitivity analyses: (i) a comparison of the frequencies of pre-existing vascular disease and other comorbidities at 1 year before cohort entry restricted to patients who had 52 years of medical history before cohort entry; (ii) an analysis of each type of vascular disease irrespective of other vascular disease types; and (iii) re-analyses of the primary results after excluding GCA patients with <6 months of follow-up and <2 treatment prescriptions as well as their corresponding comparison patients.
All analyses were conducted using SAS statistical software, version 9.3 (SAS Institute, Cary, NC, USA), and the statistical package R with an add-on cmprsk package, version 3.1.1 (www.r-project.org).
Results
We included 9778 GCA patients (72% female) and 92 268 non-vasculitis comparison patients in the analysis. Table 1 shows the baseline characteristics of study patients. GCA patients were more likely to be current or former smokers compared with non-vasculitis patients. In the year before cohort entry, 56 and 24% of GCA patients received two or more prescriptions for anti-hypertensive medicine and aspirin, respectively, significantly higher than non-vasculitis patients. Mean follow-up was 5.7 years among GCA patients and 6.2 years among non-vasculitis patients.
Pre-existing vascular disease and other comorbidities Table 2 shows frequencies of pre-existing vascular disease and other comorbidities in the GCA and comparison patients. GCA patients were more likely to have histories of all types of vascular disease except MI compared with non-vasculitis patients. They were also more likely to have all other comorbidities except type 2 diabetes, obesity and cancer. Note that around 17% of GCA patients had PMR, more than that in non-vasculitis patients (2%). When we stratified by sex, there were no significant differences in males with respect to atherosclerosis, aortic aneurysm, VTE, atrial fibrillation, hypertension and dyslipidaemia between GCA patients and their comparison patients. However males only accounted for 28% of GCA patients and thus differences were driven by female patients. Male patients with GCA were more likely to have a history of cancer compared with their comparison patients, while female patients with GCA were less likely to have a history of cancer (see Supplementary Table S1 , available at Rheumatology Online). When we stratified by age, GCA patients aged <65 years were more likely to have a history of MI, type 2 diabetes and obesity compared with their comparison patients. There were no significant differences in presence of atherosclerosis, aortic aneurysm and VTE between GCA patients aged 580 years and their comparison patients (see Supplementary Table S2 , available at Rheumatology Online).
Incident vascular disease and other comorbidities
After excluding patients with pre-existing vascular disease there were 6796 GCA and 70 388 comparison patients in the analyses of cumulative incidence for each type of vascular disease. Their baseline characteristics are provided in Supplementary Table S3 , available at Rheumatology Online. The cumulative incidences for all types of vascular disease were significantly higher in GCA than in the comparison patients. The cumulative incidences of all other comorbidities except psoriasis and cancer were also significantly higher in GCA patients ( (Table 4) . Consistent with the cumulative incidences for all other comorbidities, GCA patients had significantly higher adjusted HRs for these comorbidities except psoriasis and cancer: adjusted HRs were 12.6 (95% CI: 11.7, 13.5) for PMR, 2.11 (95% CI: 1.77, 2.51) for RA and 1.44 (95% CI: 1.33, 1.57) for type 2 diabetes (Table 5 ). When we stratified by sex, male patients with GCA, unlike the female patients, had no significantly increased risks for angina pectoris and hypertension. Adjusted HRs were similar across age strata for vascular diseases and other comorbidities of interest (Supplementary Tables S4S6, available at Rheumatology Online).
Sensitivity analyses
The frequencies of all types of vascular disease and other comorbidities present at 1 year before cohort entry www.rheumatology.oxfordjournals.org were lower in both cohorts of GCA and comparison patients when we restricted the analysis to patients with 52 years of medical history before the cohort entry, but the main findings were unchanged (Supplementary Table  S7 , available at Rheumatology Online). There were no material changes in results of the sensitivity analyses (data not shown), where we assessed each type of vascular disease separately irrespective of other vascular disease types or in the analysis that excluded GCA patients with <6 months of follow-up and less than two treatment prescriptions.
Discussion
In this large population-based cohort study we found that pre-existing vascular disease and other comorbidities were more common in GCA patients at their initial diagnosis, and that the risks were elevated for incident vascular disease and other incident comorbidities (such as type 2 diabetes, depression, etc.) after GCA diagnosis compared with the non-vasculitis patients.
Using the CPRD, Robson et al. [8] found that GCA patients were more likely to have histories of cardiovascular disease, cerebrovascular disease, PVD, hypertension, hyperlipidaemia and diabetes than non-GCA patients. In our study vascular diseases except MI were also more common in GCA patients at their initial diagnosis, and even at 1 year before the initial diagnosis. Compared with the non-vasculitis patients, GCA patients were more likely to receive prescriptions for aspirin and antihypertensive drugs before cohort entry, which may explain why MI was not more common in GCA than in comparison patients. It should be noted, however, that history of MI was more common in the youngest GCA patients (age group 5064 years) than in their matched comparison patients. We also observed that GCA patients had more of all other comorbidities except type 2 diabetes, obesity and cancer before cohort entry than the comparison patients. When we re-examined prior diabetes (including types 1 and 2), there was still no difference between GCA patients and their comparison patients. Robson et al. included treated diabetes only, which may explain the differences even though we both used the CPRD. Some studies, including a meta-analysis review, reported a lower prevalence of prior diabetes in GCA patients compared with non-GCA reference subjects [11, 2426] , while other studies reported equal or higher prevalence of diabetes in GCA patients before diagnosis [7, 8, 13] . Differences in the data sources and methods for identifying diabetes may explain these discrepancies. There are several possibilities that could explain why vascular disease was more common before cohort entry in GCA patients. First, there may be subclinical vascular inflammation in GCA preceding symptom onset, and this sub-clinical inflammation likely underlies the increased risk for many different vascular events. Second, some risk factors such as smoking, hypertension and hyperlipidaemia were also more commonly present before the GCA diagnosis and these risk factors may at least partially account for higher proportions of pre-existing vascular disease in GCA patients. Third, GCA and vascular disease may share a common aetiology. Some studies have demonstrated that RA and cardiovascular disease share genetic risk factors [2729]. Kerola et al. [30] reported that the prevalence of cardiovascular disease was already augmented in RA patients at disease diagnosis, though Holmqvist et al. [31] did not find any evidence of an increased risk of cardiovascular disease before the onset of RA symptoms. To our knowledge, there were no studies that have formally investigated pre-existing vascular disease in vasculitis. Whether a shared genetic risk factor exists for vascular disease and GCA needs further study. Some studies reported that GCA was associated with increased risk of various types of vascular disease including MI [7, 10] , PVD [6, 7, 32] , cerebrovascular disease [6, 7, 10] , aortic aneurysm [5, 6, 8] and VTE [9] , while others, including a meta-analysis, reported no increased risks [1114] . In our study GCA patients had 1.4-to 2.0-fold risks for a wide range of incident vascular diseases after controlling for many risk factors (such as smoking and other comorbidities). Robson et al. [8] , using the CPRD, evaluated the relationship between GCA and aortic aneurysm only and reported that GCA patients had an adjusted HR of 1.92 for aortic aneurysm compared with non-GCA patients. The adjusted HR (1.98) for aortic aneurysm was similar in our study. There is mounting evidence that patients with chronic inflammatory conditions are at increased risk of vascular events, and the potential mechanisms include detrimental effects of inflammatory cytokines, oxidative stress and activated leucocytes on endothelial function and proatherosclerotic effects of glucocorticoids [33] . In our study GCA was also associated with increased risks for many other comorbidities such as hypertension, type 2 diabetes, PMR and RA. Many experts consider PMR and GCA to be different manifestations of the same disease process, while others see them as closely related but different diseases [34] . We acknowledge, though, that PMR and GCA may be considered part of the same disease process and not just merely coexist. As expected a high proportion of GCA patients had PMR either before (17%) or after (19%) the initial diagnosis and GCA patients had a strong increased risk of developing PMR. GCA patients also had an increased risk of developing RA. The coexistence of RA and GCA has long been reported [35, 36] . Further, PMR and GCA share the polymorphism encoded by the second hypervariable region of the HLA-DRB1 gene [37] , seronegative late onset RA and PMR have a similar HLA-DRB1 association [38] , and DRB1*04 is associated with development of both late onset RA and GCA [39] . Whether the increased risk is because they share the same genetic factors or there were misdiagnoses between PMR and RA given the similar clinical presentations needs further evaluation. In our study GCA patients had a 1.4-fold increased risk of developing type 2 diabetes, potentially related to the typical glucocorticoids used in GCA. However, since GCA patients were more likely to have medical visits than non-vasculitis patients we cannot rule out the possibility that GCA patients had more opportunities to be examined for type 2 diabetes. In addition, increased risks for hypertension, dyslipidaemia, obesity and depression in GCA patients may also be related to glucocorticoid therapy, although we cannot rule out the possibility that GCA itself may play a role in these increased risks. Because GCA patients had increased risks for MI, heart failure, hypertension and type 2 diabetes, which are also common risk factors for atrial fibrillation, the increased risk of atrial fibrillation may be attributed to GCA-related vascular disease or other comorbidities. GCA was also reported to cause myocarditis, which may also explain increased risk of atrial fibrillation [40, 41] . In a meta-analysis Ungprasert et al. reported a marginally increased risk of malignancy among patients with GCA and/or PMR. When they excluded one study with potential selection bias, the risk did not achieve statistical significance [42] . In our study there was no difference in prior cancer or risk of incident cancer between patients with and without GCA. Our study has several strengths worth emphasizing. First, using the CPRD, which collects longitudinal medical information from general practices, allowed us to efficiently distinguish between pre-existing and incident morbidity and to explore many possible contributing factors involved with the burden of GCA. Different from previous studies, we found that vascular diseases and its risk factors are already more common at the time of GCA diagnosis, and even 1 year before the diagnosis, compared with non-vasculitis patients. Second, previous studies typically focused on GCA in relation to risks of one or multiple vascular diseases, while our study assessed 9 types of vascular disease and 11 other comorbidities that are risk factors for vascular disease, thus allowing us to better understand the associations between GCA and vascular disease. We demonstrated that GCA was associated with increased risks not only for vascular diseases, but also for many other comorbidities. Third, as GCA is a rare disease, reliable epidemiological studies on subpopulations of sex and age were limited. Because this study established a large cohort of GCA patients we also explored the associations between GCA and vascular disease and other comorbidities in subpopulations and found marked difference by sex and age, which warrant further study. Our study also has limitations. First, there may be misclassification of GCA cases, vascular diseases, or other comorbidities. However, the diagnosis codes for GCA and most of the vascular diseases and comorbidities have been previously validated in the CPRD and their positive predictive values ranged from 76.4 to 98.6%, except for atrial fibrillation where the positive predictive value was only 64% [17, 19] . Since any misclassification was likely to be non-differential, the results are likely to be biased towards the null and cannot explain the differences found in this study. It is also possible that we misclassified some obese cases since 25% of study subjects had missing data on BMI. Second, if patients presented with very severe disease and then died shortly thereafter, a diagnosis of GCA may never have been made and we would have missed these cases. Third, there was a risk of detection bias in this study whereby GCA patients may have had more medical examinations and thus been more likely to be diagnosed with other vascular diseases or comorbidities. However, GCA patients did not have increased risks for psoriasis or cancer. Moreover, GCA patients already had more prior vascular disease and other comorbidities even 1 year before cohort entry; therefore, these results are not likely to be explained solely by detection bias. Finally, although glucocorticoids were a risk factor for many study outcomes, we did not adjust for glucocorticoid use when we evaluated the associations between GCA and each incident vascular disease and comorbidity under study because glucocorticoid treatment was part of the definition of GCA. Thus we cannot distinguish the independent role of GCA itself from its relevant treatment.
In summary, GCA patients had more vascular disease and other comorbidities before the initial diagnosis and they also had increased risks for incident vascular disease and many other comorbidities after the diagnosis compared with a matched non-vasculitis population.
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